Endostemonine I as a Multi-Target Inhibitor of Kaposi’s Sarcoma-Associated Herpesvirus Oncogenic Pathways: An Integrative Computational Study
Medical Sciences · 04.05.2026 · 14 (2) · 237
DOI: 10.3390/medsci14020237 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Sciences, online erschienen am 04.05.2026. Verfasst von Imran Sama-Ae und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Technology, School of Allied Health Sciences, Walailak University, Tha Sala District, Nakhon Si Thammarat 80160, Thailand. Hauptthemen laut MEDLINE: Herpesvirus 8, Human, Sarcoma, Kaposi. Die Arbeit nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Kaposi’s sarcoma (KS) is an angioproliferative malignancy caused by Kaposi’s sarcoma-associated herpesvirus (KSHV), characterized by aberrant angiogenesis, chronic inflammation, and endothelial cell transformation. Given the multi-factorial nature of KS pathogenesis, strategies that simultaneously modulate multiple mo-lecular targets are considered more promising than single-target approaches. However, effective multi-target therapeutic agents for KS remain limited, prompting this study to employ an integrative in silico pipeline.
Methods
An integrative in silico pipeline combining compound screening, target predic-tion, network pharmacology, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Ge-nomes (KEGG) enrichment, protein–protein interaction (PPI) analysis, molecular docking, and molecular dynamics (MD) simulations was employed. Streptomyces-derived metabolites were prioritized based on chemical diversity, annotation, and clinical prece-dent. Predicted targets were intersected with KS-associated genes, with hubs ranked by network topology. Docking and MD simulations evaluated binding affinity and stability.
Results
Endostemonine I emerged as the top candidate, engaging nine of ten hub proteins, including EGFR, mTOR, PTGS2, SRC, PARP1, PPARγ, MAPK1, MAPK14, and ICAM1. Key nodes such as mTOR, PTGS2, PPARγ, and MAPK14 are central to KS-related an-gi-ogenesis, inflammation, and viral oncogenesis. GO and KEGG analyses revealed en-richment in kinase activity, cell adhesion, and PI3K–Akt/mTOR and MAPK signaling pathways. Docking indicated strong binding to mTOR, PTGS2, PARP1, PPARγ, and MAPK14, while MD simulations confirmed stable interactions for mTOR, PTGS2, PPARγ, and MAPK14.
Conclusions
Collectively, these proteins represent high-confidence, druggable KS targets, with Endostemonine I as a promising multi-target scaffold. These findings highlight the therapeutic potential of Endostemonine I and warrant further validation through future in vitro and in vivo studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Technology, School of Allied Health Sciences, Walailak University, Tha Sala District, Nakhon Si Thammarat 80160, Thailand.
- Center of Excellence Research for Melioidosis and Microorganisms (CERMM), Walailak University, Tha Sala District, Nakhon Si Thammarat 80160, Thailand.
- Kapho Hospital, Kapho District, Pattani 94230, Thailand.
- Research Excellence Center for Innovation and Health Products (RECIHP), Walailak University, Tha Sala District, Nakhon Si Thammarat 80160, Thailand.
- Drukier Institute for Children's Health, Weill Cornell Medicine, New York, NY 10021, USA.
- Hematology and Transfusion Science Research Center (HTSRC), Walailak University, Tha Sala District, Nakhon Si Thammarat 80160, Thailand.
ORCID-Profile: Imran Sama-Ae, Siriruk Changrob, Pattamaporn Kwankaew, Malatee Tayeh
Zitieren
APA
Sama-Ae, I., Daloh, M., Tedasen, A., Changrob, S., Lertcanawanichakul, M., Kwankaew, P., Issaro, P., Maidam, N., Rattanapong, N., Auma, N., Kaseng, M., & Tayeh, M. (2026). Endostemonine I as a Multi-Target Inhibitor of Kaposi’s Sarcoma-Associated Herpesvirus Oncogenic Pathways: An Integrative Computational Study. Medical Sciences, 14(2), 237. https://doi.org/10.3390/medsci14020237
Vancouver
Sama-Ae I, Daloh M, Tedasen A, Changrob S, Lertcanawanichakul M, Kwankaew P, et al. Endostemonine I as a Multi-Target Inhibitor of Kaposi’s Sarcoma-Associated Herpesvirus Oncogenic Pathways: An Integrative Computational Study. Medical Sciences. 2026;14(2):237. doi:10.3390/medsci14020237
BibTeX
@article{SamaAe2026,
author = {Sama-Ae, Imran and Daloh, Mollaya and Tedasen, Aman and Changrob, Siriruk and Lertcanawanichakul, Monthon and Kwankaew, Pattamaporn and Issaro, Phenphitcha and Maidam, Natthanicha and Rattanapong, Nichakan and Auma, Nurul and Kaseng, Mirfart and Tayeh, Malatee},
title = {Endostemonine I as a Multi-Target Inhibitor of Kaposi’s Sarcoma-Associated Herpesvirus Oncogenic Pathways: An Integrative Computational Study},
journal = {Medical Sciences},
year = {2026},
volume = {14},
number = {2},
pages = {237},
doi = {10.3390/medsci14020237}
}
EUVIMED